Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy

Acta Dermato-Venereologica

Volumn 90, Issue 2, 2010, Pages 202-203

  Eames, Tatiana ^a   Kroth, Julia ^a   Flaig, Michael J ^a   Ruzicka, Thomas ^a   Wollenberg, Andreas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FUSIDIC ACID; NADIFLOXACIN; OXALIPLATIN; PANITUMUMAB; PREDNICARBATE;

ACNE; ADULT; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLORECTAL CARCINOMA; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LETTER; PERIFOLLICULAR XANTHOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT DURATION; XANTHOMA;

ADENOCARCINOMA; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; CHEEK; COLORECTAL NEOPLASMS; DRUG ERUPTIONS; FEMALE; HUMANS; NECK; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; XANTHOMATOSIS;

EID: 77950207264     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0792     Document Type: Letter

References (9)

1. Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
2. Klein E, Tietze J, Wollenberg A. Cutaneous side effects of EGFR inhibitors and their management. Allergo J 2006; 15: 559-565.
3. Bierhoff E, Seifert HW, Dirschka T. Hautveränderungen nach Blockade des Epidermal-growth-factor-Rezeptors. Pathologe 2006; 27: 53-56.
4. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacoutre M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16: 16-26.
5. Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3: 599-606.
6. Bunn PA, Frankling W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29: 38-44.
7. Braun-Falco M, Holtmann C, Lordick F, Ring J. Follikuläre Arzneimittelreaktion auf Cetuximab. Hautarzt 2006; 57: 701-704.
8. Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-670.
9. Gutzmer R, Wefel T, Kapp A, Elsner J. Kutane Nebenwirkungen einer EGF-Rezeptor-Blockade und deren Management. Hautarzt 2006; 57: 509-513.